Drug notes:
Also Clin0 ALS, PD ; BMD-0131 RD FTD; BMD-0231 RD PD and synucleinopathies; BMD-0311 RD Epilepsy; BMD-0431 RD glaucoma; BIOK-0031 RD CNS disease; BIOK-0221 RD CNS disease
About:
Biorchestra is developing treatments for neurodegenerative and rare central nervous system diseases. Their proprietary Brain Targeting Drug Delivery System platform technology enables the delivery of nanomedicines, carrying RNA drug cargos, across the blood brain barrier, through a natural transporter, to targeted brain cells. The programs in their pipeline utilize RNA interference technology for their therapeutic strategies. Biorchestra identified the first microRNA linked to neurodegenerative diseases. The company was founded by Dr. Branden Ryu in 2016 with current facilities located in South Korea and Cambridge, Massachusetts.